Humoral Immunity Panel II
Secondary testing for the evaluation of patients with recurrent and chronic infections, for whom immunoglobulin testing has already been performed.
New York DOH Approval Status
Serum separator tube.
Transfer two 1 mL aliquots of serum to individual ARUP standard transport tubes. (Min: 0.1 mL/aliquot)
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 60 days (avoid repeated freeze/thaw cycles).
Semi-Quantitative Multiplex Chemiluminescent Immunoassay/Semi-Quantitative Multiplex Bead Assay
A pre- and postvaccination comparison is required to adequately assess the humoral immune response to the pure polysaccharide Pneumovax 23 (PNX) and/or the protein conjugated Prevnar 7 (P7), Prevnar 13 (P13), Prevnar 20 (P20), and Vaxneuvance (V15) Streptococcus pneumoniae vaccines. Prevaccination samples should be collected prior to vaccine administration. Postvaccination samples should be obtained at least 4 weeks after immunization. Testing of postvaccination samples alone will provide only general immune status of the individual to various pneumococcal serotypes.
In the case of pure polysaccharide vaccine, indication of immune system competence is further delineated as an adequate response to at least 50 percent of the serotypes in the vaccine challenge for those 2-5 years of age and to at least 70 percent of the serotypes in the vaccine challenge for those 6-65 years of age. Individual immune response may vary based on age, past exposure, immunocompetence, and pneumococcal serotype.
Responder Status Antibody Ratio
Nonresponder . . . . . . . . . . . Less than twofold increase and postvaccination concentration less than 1.3 ug/mL
Good responder . . . . . . . . . . .At least a twofold increase and/or a postvaccination concentration greater than or equal to 1.3 ug/mL
A response to 50-70 percent or more of the serotypes in the vaccine challenge is considered a normal humoral response. (Daly, 2014) Antibody concentration greater than 1.0-1.3 ug/mL is generally considered long-term protection. (Daly, 2015)
1. Daly TM, Pickering JW, Zhang X, et al. Multilaboratory assessment of threshold versus fold-change algorithms for minimizing analytical variability in multiplexed pneumococcal IgG measurements. Clin Vaccine Immunol. 2014;21(7):982-988.
2. Daly TM, Hill HR. Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function. Clin Vaccine Immunol. 2015;22(2):148-152.
|Diphtheria Antibody, IgG||Antibody concentration of >0.1 IU/mL is usually considered protective.|
|Tetanus Antibody, IgG||Antibody concentration of >0.1 IU/mL is usually considered protective.|
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0050210||Diphtheria Antibody, IgG||13227-4|
|0050535||Tetanus Antibody, IgG||53935-3|
|0050706||Pn serotype 1 IgG (P13,P20,PNX,V15)||85954-6|
|0050708||Pn serotype 4 IgG (P7,P13,P20,PNX,V15)||86107-0|
|0050709||Pn serotype 5 IgG (P13,P20,PNX,V15)||86130-2|
|0050713||Pn serotype 6B IgG (P7,P13,P20,PNX,V15)||27118-9|
|0050715||Pn serotype 3 IgG (P13,P20,PNX,V15)||86080-9|
|0050716||Pn serotype 7F IgG (P13,P20,PNX,V15)||25296-5|
|0050717||Pn serotype 9N IgG (PNX)||86169-0|
|0050718||Pn serotype 14 IgG (P7,P13,P20,PNX,V15)||85991-8|
|0050719||Pn Serotype Interpretation||42771-6|
|0050721||Pn serotype 8 IgG (P20,PNX)||86147-6|
|0050722||Pn serotype 9V IgG (P7,P13,P20,PNX,V15)||30153-1|
|0050723||Pn serotype 12F IgG (P20,PNX)||85977-7|
|0050724||Pn serotype 18C IgG (P7,P13,P20,PNX,V15)||27395-3|
|0050726||Pn serotype 19F IgG (P7,P13,P20,PNX,V15)||86024-7|
|0050727||Pn serotype 23F IgG (P7,P13,P20,PNX,V15)||86064-3|
- Diphtheria Antitoxoid
- Diphtheria IgG
- Strep Pneumoniae
- Tetanus Antitoxoid
- Tetanus IgG